Clinical benefit with intraoperative radiotherapy combined with regional chemotherapy for advanced pancreatic carcinoma

Huafeng Kang; Xijing Wang; Zhijun Dai; Xiaoxu Liu; Xinghuan Xue; Fengjie Xue; Zongzheng Ji

doi:10.1007/BF02835459

Clinical benefit with intraoperative radiotherapy combined with regional chemotherapy for advanced pancreatic carcinoma

Huafeng Kang
, Xijing Wang
, Zhijun Dai
, Xiaoxu Liu
, Xinghuan Xue
, Fengjie Xue
, Zongzheng Ji

Health Science Center

Xi'an Jiaotong University

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: To evaluate the effectiveness of intraoperative radiotherapy (IORT) in combination with regional chemotherapy in the treatment of advanced pancreatic carcinoma. Methods: 17 patients with advanced pancreatic adenocarcinoma were treated with IORT and regional chemotherapy with 5-FU, Epirubucin and Mitomycin, and 6 cases accepted external radiotherapy postoperatively. Results: 35.29% (6/17) of the patients were clinical benefit responders and 23.53% (4/17) had a partial response. The median survival time was 11 months and the 1-year survival rate was 35.29% (6/17). Conclusion: IORT in combination with regional chemotherapy had a good impact on clinical benefit without severe side effects in locally advanced pancreatic carcinoma and led to a significant prolongation of the survival time.

Original language	English
Pages (from-to)	213-215
Number of pages	3
Journal	Chinese-German Journal of Clinical Oncology
Volume	2
Issue number	4
DOIs	https://doi.org/10.1007/BF02835459
State	Published - Dec 2003

Keywords

Chemotherapy
Intraoperative radiotherapy
Pancreatic cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF02835459

Cite this

@article{902e80015dc34e51a4cad93eeadb34a6,

title = "Clinical benefit with intraoperative radiotherapy combined with regional chemotherapy for advanced pancreatic carcinoma",

abstract = "Objective: To evaluate the effectiveness of intraoperative radiotherapy (IORT) in combination with regional chemotherapy in the treatment of advanced pancreatic carcinoma. Methods: 17 patients with advanced pancreatic adenocarcinoma were treated with IORT and regional chemotherapy with 5-FU, Epirubucin and Mitomycin, and 6 cases accepted external radiotherapy postoperatively. Results: 35.29\% (6/17) of the patients were clinical benefit responders and 23.53\% (4/17) had a partial response. The median survival time was 11 months and the 1-year survival rate was 35.29\% (6/17). Conclusion: IORT in combination with regional chemotherapy had a good impact on clinical benefit without severe side effects in locally advanced pancreatic carcinoma and led to a significant prolongation of the survival time.",

keywords = "Chemotherapy, Intraoperative radiotherapy, Pancreatic cancer",

author = "Huafeng Kang and Xijing Wang and Zhijun Dai and Xiaoxu Liu and Xinghuan Xue and Fengjie Xue and Zongzheng Ji",

year = "2003",

month = dec,

doi = "10.1007/BF02835459",

language = "英语",

volume = "2",

pages = "213--215",

journal = "Chinese-German Journal of Clinical Oncology",

issn = "1610-1979",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Clinical benefit with intraoperative radiotherapy combined with regional chemotherapy for advanced pancreatic carcinoma

AU - Kang, Huafeng

AU - Wang, Xijing

AU - Dai, Zhijun

AU - Liu, Xiaoxu

AU - Xue, Xinghuan

AU - Xue, Fengjie

AU - Ji, Zongzheng

PY - 2003/12

Y1 - 2003/12

N2 - Objective: To evaluate the effectiveness of intraoperative radiotherapy (IORT) in combination with regional chemotherapy in the treatment of advanced pancreatic carcinoma. Methods: 17 patients with advanced pancreatic adenocarcinoma were treated with IORT and regional chemotherapy with 5-FU, Epirubucin and Mitomycin, and 6 cases accepted external radiotherapy postoperatively. Results: 35.29% (6/17) of the patients were clinical benefit responders and 23.53% (4/17) had a partial response. The median survival time was 11 months and the 1-year survival rate was 35.29% (6/17). Conclusion: IORT in combination with regional chemotherapy had a good impact on clinical benefit without severe side effects in locally advanced pancreatic carcinoma and led to a significant prolongation of the survival time.

AB - Objective: To evaluate the effectiveness of intraoperative radiotherapy (IORT) in combination with regional chemotherapy in the treatment of advanced pancreatic carcinoma. Methods: 17 patients with advanced pancreatic adenocarcinoma were treated with IORT and regional chemotherapy with 5-FU, Epirubucin and Mitomycin, and 6 cases accepted external radiotherapy postoperatively. Results: 35.29% (6/17) of the patients were clinical benefit responders and 23.53% (4/17) had a partial response. The median survival time was 11 months and the 1-year survival rate was 35.29% (6/17). Conclusion: IORT in combination with regional chemotherapy had a good impact on clinical benefit without severe side effects in locally advanced pancreatic carcinoma and led to a significant prolongation of the survival time.

KW - Chemotherapy

KW - Intraoperative radiotherapy

KW - Pancreatic cancer

UR - https://www.scopus.com/pages/publications/84873398704

U2 - 10.1007/BF02835459

DO - 10.1007/BF02835459

M3 - 文章

AN - SCOPUS:84873398704

SN - 1610-1979

VL - 2

SP - 213

EP - 215

JO - Chinese-German Journal of Clinical Oncology

JF - Chinese-German Journal of Clinical Oncology

IS - 4

ER -

Clinical benefit with intraoperative radiotherapy combined with regional chemotherapy for advanced pancreatic carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this